• 2006

Company Description

OrPro Therapeutics develops recombinant thioredoxin for the treatment of cystic fibrosis.

OrPro Therapeutics,Inc. is a pre-­‐clinical stage biopharmaceutical company headquartered in San Diego,CA. The company’s goal is to develop a breakthrough class of safe,well-­‐tolerated and more effective inhaled non-­‐systemic drugs based on the thioredoxin active site for the treatment of patients with cystic fibrosis (CF),COPD/emphysema, bronchiectasis,severe asthma, and other serious obstructive pulmonary diseases.